StockData

ANI Pharmaceuticals vs Kiniksa Pharmaceuticals International

ANIP and KNSA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ANIP and KNSA compare

Kiniksa Pharmaceuticals International is the larger company, worth 9.3 times as much as ANI Pharmaceuticals ($14.9B against $1.6B).

On earnings, ANI Pharmaceuticals is cheaper: it trades at 14.9× trailing earnings, against 73.2× for Kiniksa Pharmaceuticals International.

Kiniksa Pharmaceuticals International grew revenue faster over the last twelve months (58.2% versus 30.9% for ANI Pharmaceuticals).

Kiniksa Pharmaceuticals International keeps more of each dollar of sales as profit, with a net margin of 11.6% compared with 11.1% at ANI Pharmaceuticals.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricANIPKNSA
Size and price
Market cap$1.6B$14.9B
Share price$69.99$95.11
Change, 1 year−16.7%136%
Change, 5 years71.7%716%
Beta (5Y)0.650.15
Employees970366
StockData Score
Total score1414
Valuation score5 (better)0
Growth score24 (better)
Performance score44
Health score36 (better)
Dividend score00
Valuation
P/E14.9× (better)73.2×
P/S1.6× (better)15.8×
P/B2.7× (better)21.0×
EV/EBITDA6.6× (better)109×
P/FCF9.3× (better)75.8×
FCF yield10.8% (better)1.3%
Fair value$133.72$16.72
Margin of safety47.7% (better)−469%
Growth
Revenue growth (TTM)30.9%58.2% (better)
Revenue growth, 5Y average33.5%–
Net income growth (TTM)–205%
EPS growth (TTM)–189%
Profitability
Gross margin60.4%90.2% (better)
Operating margin15.4% (better)13.8%
Net margin11.1%11.6% (better)
FCF margin17.7%20.8% (better)
Return on equity21.0% (better)17.6%
Return on invested capital21.3%60.2% (better)
Financial health
Debt / equity0.50 (better)0.00
Net debt / EBITDA−0.25–
Interest coverage4.8×–
Current ratio2.913.91 (better)
Altman Z-score2.5334.40 (better)
Piotroski F-score78 (better)
Dividends and buybacks
Payout ratio0.32%–
Buyback yield1.4%–
Shareholder yield1.4% (better)0.00%
Ownership
Held by institutions100%29.9%
Held by insiders12.3%5.1%
Insider net buying, 12 months−$13.6M (better)−$122M
Short interest, % of float17.8%2.9%

Go deeper

Other comparisons

For information only, not investment advice. Check the source filings before relying on any figure.